510 related articles for article (PubMed ID: 32733014)
21. The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms.
Belčič Mikič T; Pajič T; Zver S; Sever M
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33806036
[No Abstract] [Full Text] [Related]
22. Calreticulin mutation does not contribute to disease progression in essential thrombocythemia by inhibiting phagocytosis.
Daitoku S; Takenaka K; Yamauchi T; Yurino A; Jinnouchi F; Nunomura T; Eto T; Kamimura T; Higuchi M; Harada N; Saito N; Miyamoto T; Iwasaki H; Akashi K
Exp Hematol; 2016 Sep; 44(9):817-825.e3. PubMed ID: 27185380
[TBL] [Abstract][Full Text] [Related]
23. [Development of myeloproliferative neoplasms by mutant calreticulin: underlying mechanisms].
Araki M
Rinsho Ketsueki; 2018; 59(8):1072-1077. PubMed ID: 30185708
[TBL] [Abstract][Full Text] [Related]
24. Getting Hot Under the CALR: What Drives Pediatric Myeloproliferative Neoplasms?
Langabeer SE
Pediatr Hematol Oncol; 2015; 32(8):513-4. PubMed ID: 26270896
[No Abstract] [Full Text] [Related]
25. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.
Loghavi S; Bueso-Ramos CE; Kanagal-Shamanna R; Ok CY; Salim AA; Routbort MJ; Mehrotra M; Verstovsek S; Medeiros LJ; Luthra R; Patel KP
Am J Clin Pathol; 2016 Mar; 145(3):418-27. PubMed ID: 27124925
[TBL] [Abstract][Full Text] [Related]
26. Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice.
Toppaldoddi KR; da Costa Cacemiro M; Bluteau O; Panneau-Schmaltz B; Pioch A; Muller D; Villeval JL; Raslova H; Constantinescu SN; Plo I; Vainchenker W; Marty C
Oncogene; 2019 Mar; 38(10):1651-1660. PubMed ID: 30846848
[TBL] [Abstract][Full Text] [Related]
27. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.
Han L; Schubert C; Köhler J; Schemionek M; Isfort S; Brümmendorf TH; Koschmieder S; Chatain N
J Hematol Oncol; 2016 May; 9(1):45. PubMed ID: 27177927
[TBL] [Abstract][Full Text] [Related]
28. Structural Analysis of Calreticulin, an Endoplasmic Reticulum-Resident Molecular Chaperone.
Houen G; Højrup P; Ciplys E; Gaboriaud C; Slibinskas R
Prog Mol Subcell Biol; 2021; 59():13-25. PubMed ID: 34050860
[TBL] [Abstract][Full Text] [Related]
29. Interference of immunogenic chemotherapy by artificially controlled calreticulin secretion from tumor cells.
Zhao L; Zhang S; Chen H; Kroemer G; Kepp O; Liu P
Methods Cell Biol; 2022; 172():99-114. PubMed ID: 36064229
[TBL] [Abstract][Full Text] [Related]
30. Type I but Not Type II Calreticulin Mutations Activate the IRE1α/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms.
Ibarra J; Elbanna YA; Kurylowicz K; Ciboddo M; Greenbaum HS; Arellano NS; Rodriguez D; Evers M; Bock-Hughes A; Liu C; Smith Q; Lutze J; Baumeister J; Kalmer M; Olschok K; Nicholson B; Silva D; Maxwell L; Dowgielewicz J; Rumi E; Pietra D; Casetti IC; Catricala S; Koschmieder S; Gurbuxani S; Schneider RK; Oakes SA; Elf SE
Blood Cancer Discov; 2022 Jul; 3(4):298-315. PubMed ID: 35405004
[TBL] [Abstract][Full Text] [Related]
31. Mutant specific anti calreticulin antibody (CAL2) immunohistochemistry as a screening test for calreticulin (CALR) mutation testing.
Rahman K; Chandra D; Singh MK; Gupta R; Sharma A; Paul P; Kumar S; Sharma S; Nityanand S
Int J Lab Hematol; 2020 Oct; 42(5):604-611. PubMed ID: 32463176
[TBL] [Abstract][Full Text] [Related]
32. The Calreticulin gene and myeloproliferative neoplasms.
Clinton A; McMullin MF
J Clin Pathol; 2016 Oct; 69(10):841-5. PubMed ID: 27354406
[TBL] [Abstract][Full Text] [Related]
33. Targeting the CALR interactome in myeloproliferative neoplasms.
Pronier E; Cifani P; Merlinsky TR; Berman KB; Somasundara AVH; Rampal RK; LaCava J; Wei KE; Pastore F; Maag JL; Park J; Koche R; Kentsis A; Levine RL
JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429377
[TBL] [Abstract][Full Text] [Related]
34. Cancer Biology of the Endoplasmic Reticulum Lectin Chaperones Calreticulin, Calnexin and PDIA3/ERp57.
Lam STT; Lim CJ
Prog Mol Subcell Biol; 2021; 59():181-196. PubMed ID: 34050867
[TBL] [Abstract][Full Text] [Related]
35. CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.
Belcic Mikic T; Pajic T; Sever M
Sci Rep; 2019 Dec; 9(1):19838. PubMed ID: 31882869
[TBL] [Abstract][Full Text] [Related]
36. Tumor-associated calreticulin variants functionally compromise the peptide loading complex and impair its recruitment of MHC-I.
Arshad N; Cresswell P
J Biol Chem; 2018 Jun; 293(25):9555-9569. PubMed ID: 29769311
[TBL] [Abstract][Full Text] [Related]
37. Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms.
Mózes R; Gángó A; Sulák A; Vida L; Reiniger L; Timár B; Krenács T; Alizadeh H; Masszi T; Gaál-Weisinger J; Demeter J; Csomor J; Matolcsy A; Kajtár B; Bödör C
Pathology; 2019 Apr; 51(3):301-307. PubMed ID: 30606612
[TBL] [Abstract][Full Text] [Related]
38. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
[TBL] [Abstract][Full Text] [Related]
39. Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface.
Masubuchi N; Araki M; Yang Y; Hayashi E; Imai M; Edahiro Y; Hironaka Y; Mizukami Y; Kihara Y; Takei H; Nudejima M; Koike M; Ohsaka A; Komatsu N
Leukemia; 2020 Feb; 34(2):499-509. PubMed ID: 31462733
[TBL] [Abstract][Full Text] [Related]
40. Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms.
Martin S; Wright CM; Scott LM
Br J Haematol; 2017 Apr; 177(1):55-66. PubMed ID: 28168700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
